CN1655821A - 包括cdk抑制剂和多柔比星的联合 - Google Patents

包括cdk抑制剂和多柔比星的联合 Download PDF

Info

Publication number
CN1655821A
CN1655821A CNA038120852A CN03812085A CN1655821A CN 1655821 A CN1655821 A CN 1655821A CN A038120852 A CNA038120852 A CN A038120852A CN 03812085 A CN03812085 A CN 03812085A CN 1655821 A CN1655821 A CN 1655821A
Authority
CN
China
Prior art keywords
doxorubicin
cdk inhibitor
proliferative disease
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038120852A
Other languages
English (en)
Chinese (zh)
Inventor
罗杰·N·斯莱
安东·伯恩斯
海伦·M·科利
斯科特·莱昂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207228A external-priority patent/GB0207228D0/en
Priority claimed from GB0222408A external-priority patent/GB0222408D0/en
Priority claimed from GB0225876A external-priority patent/GB0225876D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of CN1655821A publication Critical patent/CN1655821A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038120852A 2002-03-27 2003-03-25 包括cdk抑制剂和多柔比星的联合 Pending CN1655821A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0207228.8 2002-03-27
GB0207228A GB0207228D0 (en) 2002-03-27 2002-03-27 Use
GB0222408.7 2002-09-26
GB0222408A GB0222408D0 (en) 2002-09-26 2002-09-26 Use
GB0225876A GB0225876D0 (en) 2002-11-06 2002-11-06 Use
GB0225876.2 2002-11-06

Publications (1)

Publication Number Publication Date
CN1655821A true CN1655821A (zh) 2005-08-17

Family

ID=28678579

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038120852A Pending CN1655821A (zh) 2002-03-27 2003-03-25 包括cdk抑制剂和多柔比星的联合

Country Status (7)

Country Link
EP (1) EP1487495A1 (fr)
JP (1) JP2005527560A (fr)
CN (1) CN1655821A (fr)
AU (1) AU2003217024A1 (fr)
BR (1) BR0308756A (fr)
MX (1) MXPA04009396A (fr)
WO (1) WO2003082337A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169720A (zh) * 2011-12-21 2013-06-26 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044275A1 (fr) * 2003-11-06 2005-05-19 Cyclacel Limited Utilisation
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
WO2007132220A1 (fr) * 2006-05-12 2007-11-22 Cyclacel Limited Combinaison de 4-hétér0aryl-pyrimidine amine substituée en 2 et d'un médicament cytotoxique, son utilisation dans le traitement d'un trouble prolifératif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044174A2 (fr) * 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company Derives de 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one et leur utilisation
US6849631B2 (en) * 2000-12-08 2005-02-01 Bristol Myers Squibb Pharma Company Semicarbazides and their uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169720A (zh) * 2011-12-21 2013-06-26 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途
CN103169720B (zh) * 2011-12-21 2016-12-07 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途

Also Published As

Publication number Publication date
JP2005527560A (ja) 2005-09-15
MXPA04009396A (es) 2005-01-25
EP1487495A1 (fr) 2004-12-22
WO2003082337A1 (fr) 2003-10-09
BR0308756A (pt) 2004-12-28
AU2003217024A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
CN103168042B (zh) 7-([1,2,3]-三唑-4-基)吡咯并[2,3-b]吡嗪衍生物
KR20010043563A (ko) 부작용 경감제
CN1441671A (zh) 用于治疗癌症的脂肪酸类似物
CN103403005A (zh) 5-([1,2,3]-三唑-4-基)-7H-吡咯并[2,3-d]嘧啶衍生物
US9433607B2 (en) Composition for prevention or treatment of cancer comprising N-methylenenaphtho[2,1-b]furan-2-carbohydrazide derivatives as an active ingredient
KR102011105B1 (ko) 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물
EP2754441B1 (fr) Composition de prévention et de traitement du cancer du poumon non à petites cellules contenant des dérivés de pyrazino-triazine
CN112566628A (zh) 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂
CN1655821A (zh) 包括cdk抑制剂和多柔比星的联合
CN110152001B (zh) 小分子化合物的用途及其组合物
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
CN1533277A (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CN1361693A (zh) 1,4－苯并硫氮杂∴衍生物作为抗癌药抗性克服用药物的用途
US12048711B2 (en) Composition and use thereof in the manufacture of medicament for treating cancer
CN1660434A (zh) 抗恶性肿瘤的药物组合物及其应用
US10857113B2 (en) Bezafibrate for the treatment of cancer
US11058645B2 (en) Inhibition of respiratory complex III by ligands that interact with a regulatory switch
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
WO2009073224A1 (fr) Procédés de traitement de certaines maladies à l'aide de dérivés de la pyrimidine
CN1652844A (zh) 用于癌症治疗的cdk抑制剂和5－fu的联合
CN101443021A (zh) 癌和其他疾病的预防和治疗
CN1615127A (zh) 取代的二环[3.3.1]壬烷－2,4,9三酮作为活性药物成分
CN101511355B (zh) (2z)-2-(3,4-二羟基亚苄基)-1-苯并呋喃-3(2h)-酮在制备抗癌药物中的应用
US7846974B2 (en) Method of lowering blood glucose and method of treating diabetes and obesity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication